IPP Bureau

OneSource Specialty Pharma appoints Jeffrey Wong as CBO
OneSource Specialty Pharma appoints Jeffrey Wong as CBO

By IPP Bureau - July 08, 2025

He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations

Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

By IPP Bureau - July 08, 2025

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need

Godavari Biorefineries' anti-cancer patent now validated in Spain and UK
Godavari Biorefineries' anti-cancer patent now validated in Spain and UK

By IPP Bureau - July 07, 2025

Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states

Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB
Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB

By IPP Bureau - July 07, 2025

CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders

Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars
Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars

By IPP Bureau - July 07, 2025

Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone

Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO
Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO

By IPP Bureau - July 07, 2025

Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries

SPARC incorporates subsidiary ‘Genokine Biotech’
SPARC incorporates subsidiary ‘Genokine Biotech’

By IPP Bureau - July 07, 2025

The wholly owned subsidiary will carry on the business of all types of research and development and other related services

GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde
GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde

By IPP Bureau - July 06, 2025

The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde

Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA
Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA

By IPP Bureau - July 06, 2025

The audit has been concluded with no major observations

Suraksha Diagnostic unveils Eastern India's largest genomics lab
Suraksha Diagnostic unveils Eastern India's largest genomics lab

By IPP Bureau - July 06, 2025

Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer
Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer

By IPP Bureau - July 06, 2025

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone

European Commission fines Alchem for participating in API cartel
European Commission fines Alchem for participating in API cartel

By IPP Bureau - July 05, 2025

The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle

Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
Faron publishes study highlighting role of sClever-1 as immune blocker in cancer

By IPP Bureau - July 04, 2025

The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells

atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression
atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression

By IPP Bureau - July 04, 2025

atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.

argenx advances clinical development of agonist antibody for myasthenic syndromes
argenx advances clinical development of agonist antibody for myasthenic syndromes

By IPP Bureau - July 04, 2025

ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept

Latest Stories

Interviews

Packaging